Protecting now from what comes next

The outbreak of COVID-19 caught the world off guard and severely constrained people's ability to live their lives to the fullest. Responses have been non-personal and broad (such as social distancing) or focused medical approaches targeting specific strains (such as vaccines). And while these solutions are crucial and these vaccines were developed at unprecedented speed, all responses are reactive.

What the world needs is a proactive approach. Nature harbors millions of unknown viruses and with virus mutations in humans, new infections are a given. However, we don’t know which one will strike next. The current reactive approach does not prepare us for these future threats.

It’s time for a new approach.

Love Hugs

our new Approach

Leyden Labs’ proactive approach protects against a broad range of viruses

To protect from what comes next, we need to act proactively and be ready for a broad range of viruses. At Leyden Labs, we expand the armamentarium of available tools by developing our platform and products with three innovative concepts:

Targeting the commonalities of viruses

The millions of unknown viruses harbored in nature can be grouped in a few dozen of viral families. By targeting the commonalities of these families, we can develop protection against entire virus families at once, including the unknown variants. Our focus is on respiratory viruses like influenza and coronaviruses, which are most likely to cause pandemics because they are transmitted through the air.

Attacking viruses where they attack us

Through our platform, we are developing nasal sprays that provide immediate protection because they attack viruses where they attack us – in our nasal passages – keeping people safe from catching infections and preventing people from spreading them to others.

Providing protection independent of people’s immune system

Through our nasal sprays we deliver antibodies in the mucosa of the nasal passages that provide the user instant protection. It does not rely on the defense of a person’s own immune system and can therefore also effectively support population groups at risk, such as elderly and immunocompromised people.

Leyden Labs’ product candidates

We are working toward accessible, self-administrable products, so people can take control and live their lives to the fullest by protecting themselves against catching infections and preventing transmission to others. In January 2022, we announced that we have an exclusive license to develop and commercialize CR9114, a pan-influenza antibody protecting against influenza A and B. We are working hard to develop our PanFlu product candidate and advance it into the clinic.

Love Sports

our team

We challenge limits

The city of Leiden (The Netherlands) inspired our name. For centuries, Leiden is known for unconventional thinking, the freedom to express this openly and scientific breakthroughs such as the first publications of Galileo’s famous Discorsi.

Our team of energetic, experienced and curious people is ready to go beyond to accomplish our mission. We strive for a fantastic life for all people. We aim for the highest, think unconventionally and focus relentlessly on delivering the impossible. In our team trust, integrity and inclusiveness are a given.

Our team

Meet our fantastic team. Together, we work towards our mission of freeing you from viruses.

Koenraad Wiedhaup

Founder and Chief Executive Officer

Jaap Goudsmit

Founder and Chief Scientific Officer

Ronald Brus

Founder and Chief Growth Officer

Suha Jhaveri

Chief Business Officer

Marieke van der Lans

Chief Financial Officer

Sanne Melles

Chief Operations Officer

Xavier Maes

General Counsel

Sagrario Arias Rivas

Research Partnerships

Anna Beukenhorst

Scientific Data

Allison Bhattacharya

Mucosal Platform Discovery

Kristian Bolk

People

Carolyn Boudreau

Mucosal Platform Discovery

Vivian Bouwer

Office Management

Marianne Busch

Preclinical & CMC

Görkem Cemali

Preclinical & CMC

María Ángeles Corral

Product Lead Discovery

Justin Crawford

Mucosal Platform Discovery

Meiling Dai

Mucosal Platform Discovery

Janine de Jong

Executive Support

Babette de Jong

Preclinical & CMC

Dennis de Vlaam

Operations

Alex Deuschel

Scientific Data

Alexander Dingenouts

IT

Virginia Fernández

Research Operations

Stephanie Fischinger

Product Lead Discovery

Jacopo Frallicciardi

Scientific Data

Carola Franso

Preclinical & CMC

Ilse Haisma

Research Operations

Alex Henriquez

IT

Hellen Houlleberghs

Clinical & Epidemiology

Javante Ishmael-Langham

Mucosal Platform Discovery

Boris Juelg

Clinical & Epidemiology

Jaco Klap

Scientific Data

Clarissa Koch

Mucosal Platform Discovery

Martin Koldijk

Scientific Data

Wouter Koudstaal

Product Lead Discovery

Zoltán Magyarics

Clinical & Epidemiology

Fergus Manford

IP

Maurice Mannesse

Preclinical & CMC

Ian McGuinness

Regulatory Affairs

Stephen Mc Nally

Quality

Joana Mello

Mucosal Platform Discovery

Guissela Moreno

Finance & Control

Amanda Motto

Finance & Control

Andrea Pastini

Clinical & Epidemiology

Keira Lee Rice

Scientific Data

Félix Risco

Product Lead Discovery

Gieta Salikram

Executive Support

Nuno Silva

Product Lead Discovery

Mihaela Solca

Laboratory Operations

Jos Vaessens

IT

Lotte van Alst

Finance & Control

Anita van den Biggelaar

Clinical & Epidemiology

Menno van Lummel

Preclinical & CMC

René Verdonk

Program Management

Carla Vogelezang

Preclinical & CMC

Lars von Oerthel

Laboratory Operations

Marianne Wooning

Clinical & Epidemiology

Soheil Yousefi

Mucosal Platform Discovery

Bertjan Ziere

Preclinical & CMC

You?

Click for our vacancies!

Our Supervisory Board

Dinko Valerio
Founder and Chair of the Supervisory Board

John Martin (In memoriam)
Former CEO Gilead Sciences

Onno van de Stolpe
Former CEO Galapagos.

James Shannon
Former CMO GSK and Global Head of Development at Novartis

Richard Whitley
Professor in Pediatrics and Microbiology, Medicine and Neurosurgery at University of Alabama

David Schenkein
General Partner GV

Stephen Knight
President and Managing Partner F-Prime Capital

Eli Casdin
Chief Investment Officer and Founder

Our investors

We are working together with a strong syndicate of investors and ambassadors. Our investors are GV (formerly Google Ventures), F-Prime Capital, Casdin Capital, Byers Capital / Brook Byers, Softbank Vision Fund 2, Invus and Bluebird Ventures.

our values

join our mission

Become part of our journey

At Leyden Labs, we want to free humanity from the burden of respiratory viruses to let people live life to the fullest. We are moving fast and growing quickly. Are you interested in contributing?